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Background. Published cost-effectiveness estimates can
vary considerably, both within and between countries.
Despite extensive discussion, little is known empirically
about factors relating to these variations. Objectives. To
use multilevel statistical modeling to integrate cost-
effectiveness estimates from published economic evalua-
tions to investigate potential causes of variation.Methods.
Cost-effectiveness studies of statins for cardiovascular dis-
ease prevention were identified by systematic review. Esti-
mates of incremental costs and effects were extracted from
reported base case, sensitivity, and subgroup analyses,
with estimates grouped in studies and in countries. Three
bivariate models were developed: a cross-classified model
to accommodate data from multinational studies, a hierar-
chical model with multinational data allocated to a single
category at country level, and a hierarchical model
excluding multinational data. Covariates at different lev-
els were drawn from a long list of factors suggested in
the literature. Results. We found 67 studies reporting
2094 cost-effectiveness estimates relating to 23 countries
(6 studies reporting for more than 1 country). Data and
study-level covariates included patient characteristics,
intervention and comparator cost, and some study meth-
ods (e.g., discount rates and time horizon). After adjusting
for these factors, the proportion of variation attributable to
countries was negligible in the cross-classified model but
moderate in the hierarchical models (14%–19% of total
variance). Country-level variables that improved the fit
of the hierarchical models included measures of income
and health care finance, health care resources, and popu-
lation risks. Conclusions. Our analysis suggested that vari-
ability in published cost-effectiveness estimates is related
more to differences in study methods than to differences
in national context. Multinational studies were associated
with much lower country-level variation than single-country
studies. These findings are for a single clinical question and
may be atypical. Key words: economic evaluation; transfer-
ability; exchangeability; multilevel statistical modeling; sta-
tins; cardiovascular disease. (Med Decis Making XXXX;
XX:xx–xx).
Decisions about the provision and reimburse-ment of health technologies are increasingly
informed by consideration of cost-effectiveness. Ide-
ally, deliberations would always be informed by
a bespoke economic evaluation, tailored to the spe-
cific decision problem of interest, using a preferred
methodological framework and integrating best evi-
dence of effectiveness with local data and assump-
tions on the epidemiological, health care, and
socioeconomic context. In practice, decision makers
do not always have the resources to commission
such exemplary economic evidence, and even
bodies that invest heavily in analysis do not have
access to a bespoke decision model to inform every
decision. For example, although the Technology
Appraisal Committees at the National Institute for
Health and Care Excellence in England do usually
have access to a bespoke model, the Clinical Guide-
lines and Public Health committees often do not. In
such cases, rather than not considering economic
evidence at all, decision makers may seek to transfer
or adapt cost-effectiveness estimates from other con-
texts. However, results of published economic eva-
luations often vary, and it is hard to know which
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estimates to rely on and whether and how they
might be combined.
Quantitative pooling of cost-effectiveness results
is not generally recommended because of concerns
over heterogeneity of methods, decision perspective,
and intervention context.1 The Cochrane Handbook
emphasizes that the preferred method to summarize
economic evidence is through tabulation of the
characteristics and results of included studies, sup-
plemented by a narrative summary.2 The GRADE col-
laboration has taken a similar position.3 Anderson
and Shemilt4 go further and argue that attempts to
pool results from multiple economic studies are fun-
damentally misguided and that the (only) good rea-
sons for conducting reviews of economic studies are
1) to inform the development of a bespoke model, 2)
to identify themost relevant study to transfer or adapt
when de novo modeling is not possible, and 3) to
understand the key economic tradeoffs and causal
relationships relevant to a decision. Shemilt and oth-
ers5(p8) suggest thatmultivariate meta-regressionmay
allow ‘‘the effects of multiple explanatory factors to
be investigated simultaneously,’’ but that ‘‘techni-
ques to explore the impact of factors likely to explain
variation in estimates of resource use, costs and
effects between studies remains under-explored for
economic data.’’
There is now a considerable literature on the trans-
ferability or generalizability of economic evaluations
of health care technologies, and many potential
factors have been suggested that may account for
variability between estimates.6,7 However, these fac-
tors are often fuzzy or difficult to measure, and little
is known empirically about their relative impor-
tance. Understanding the factors relating to variabil-
ity in published estimates of cost-effectiveness is not
just of academic interest to health economists but
may potentially help decision makers to decide
what aspects of published economic evaluations
are most important when deciding whether or not
to transfer or adapt results to their context and, if
so, which of the available estimates is most relevant
for them.
This article aims to explore variation in estimates
of incremental costs (DC) and incremental effects
(DE) between studies and countries using a multi-
level-modeling (MLM) approach. We were interested
in the extent of intercountry variation in cost-effec-
tiveness estimates, after controlling for population,
intervention, and methodological differences within
and between studies. We also sought to explore
whether between-country variation could be
explained by any measureable national characteris-
tics (such as gross domestic product [GDP] per head
or expenditure on health care).
MLM is not new to health economics.8,9 The
method has been applied to analyze individual
patient data (IPD) from economic evaluations con-
ducted alongside multinational randomized con-
trolled trials (RCTs),6,10–16 cluster randomized
trials,17–19 and multicentre observational studies.20–23
Studies have used resource use,20 cost,11,16,20,22 or net
monetary benefit6,12,17,21 as a response variable or
estimated incremental costs (DC) and incremental
effects (DE) simultaneously in a bivariate frame-
work.10,13–15,17,19,21 A 2-level hierarchical data
structure is common, with patient data grouped in
centers,6,13,16,20–23 patient clusters,17–19 or coun-
tries.10,11,14,15Our contribution extended this approach,
drawing from research on school performance,24 to use
3-level hierarchical and cross-classified model struc-
tures with published cost-effectiveness estimates
groupedwithin studies and countries. The hierarchical
model structure requires that studies are nested within
countries—that each study provides estimates for 1
and only 1 country. The cross-classified model
allows the inclusion of results from multinational
studies, which report estimates for more than 1
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country. We compare the results from these model
structures.
We applied ourmodels to a set of published results
derived from a systematic review of economic evalu-
ations on the use of statins for the prevention of car-
diovascular disease (CVD). Statins were deliberately
chosen as we knew that they had been extensively
studied and that many cost-effectiveness estimates
would be available for many countries, thus increas-
ing power for our analyses. The results are therefore
illustrative and should not be seen as typical for other
interventions or disease areas. The studies that we
used included both trial-based economic evaluations
(based on an analysis of IPD from a single RCT) and
model-based evaluations (inwhich estimates of treat-
ment effects from a trial or meta-analysis of trials
were combined with parameter estimates from other
sources in a decision model). From each study, we
extracted pairs of (DC, DE) estimates for the base
case analysis and for each reported subgroup and
deterministic sensitivity analysis. Thus, each study
could yield more than 1 data point for analysis, pro-
viding information about how the factors defining
the different subgroup or sensitivity analyses contrib-
uted to variation in the study estimates. This use of
published cost-effectiveness estimates allowed us to
investigate the impact of methodological differences
between studies, which has been previously identi-
fied as an important source of variability,25 alongside
intercountry variation.
Like all MLM, our approach relies on an assump-
tion of exchangeability,26 that is, that there are ‘‘no
a priori reasons why one jurisdiction may have
more or less favourable measures of costs or cost-
effectiveness than another.’’27(p413) Within the
MLM framework, we can model exchangeability
while also controlling for variation within studies,
between studies, and between countries through the
assumption of conditional independence.10,28,29
This allows quantification of the impact of variability
factors on data, study, and country level. However,
a fundamental difference between our study and the
above applications of MLM was the unit of analysis:
previous studies analyzed data for individual
patients, while we analyzed summary estimates of
(mean) incremental costs (DC) and health effects
(DE) reported in published economic evaluations.
Our analysesmay be seen as a formofmeta-regression
but with the difference that it was not possible to
incorporate the precision of each published estimate
of DC and DE. Most studies in our data set (61 out of
67) relied on decision modeling rather than observa-
tions from IPD, and estimates of precision based on
sampling variation are not available for these studies.
This issue is addressed in the Discussion section
below.
In the followingMethods section,we describe how
the data set was obtained from a systematic review,
specify alternative model structures, and explain
how potential explanatory variables were derived
from the literature. In the Results, we describe the sta-
tins data set, compare the fit of the alternative model
specifications without covariates, investigate how
the level of country variation changes with the inclu-
sion of covariates at data and study level, and finally
assess some covariates at country level. The Discus-
sion highlights the strength and weaknesses of our
approach, puts our findings in the context of existing
literature, and outlines potential policy implications
and areas for further research.
METHODS
Derivation of the Data Set
We conducted a systematic literature review to
identify cost-effectiveness estimates for statins in
the prevention of CVD. A sensitive search strategy
was used to identify as many economic evaluations
for as many countries as possible. A search of elec-
tronic databases (OVID, PubMed, SCOPUS, Web of
Science, HEED, CRD, NHS EED, Biosis, EBSCO, and
Cochrane) was conducted using search terms from
a published review.30 Reviews were also hand
searched to identify any additional studies. Studies
were included if they compared a statin with ‘‘doing
nothing,’’ ‘‘another statin,’’ or ‘‘the same statin in
a different dosage’’ in an adult population and if
point estimates of mean incremental costs DC and
effects DE could be retrieved, with effectiveness mea-
sured either in life-years saved or quality-adjusted
life-years (QALYs). Studies using trial-based IPD
and decision analytic modeling studies were
included. Studies that adapted published results to
other countries were included if results were not sim-
ply currency-adjusted equivalents of the original data.
We did not apply further study quality criteria, as we
intended to control for study quality using the Quality
of Health Economic Studies (QHES) instrument.31
Cost-effectiveness estimates were extracted for the
base case and for reported subgroup and sensitivity
analyses; thus, each study contributed 1 or more
point estimates of (DC, DE). Each data point was asso-
ciated with a target country, but some multinational
studies reported estimates for more than 1 country.
Local currencies were transferred to Pounds Sterling
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using purchasing power parities and updated to 2010
using country-specific GDP deflators.32,33 For Euro-
zone countries, historic currencies were converted
to Euros using irrevocable conversion rates.34
Definition of Covariates
Potential explanatory variables were identified
from a list of 77 variability factors suggested in previ-
ous publications.6,7 We coded about 200 measurable
indicators of these factors in a data abstraction form
and applied this on a pilot data set of 16 studies. Var-
iables that were not frequently reported or did not
vary between studies were dropped, resulting in
a final set of 59 variables for which data were
extracted from the study reports. Finally, country-
level variables were added from databases of interna-
tional statistics.35,36
The final list of 71 candidate variables is shown in
Supplementary Appendix A. At the data level, there
were measures of patient and disease characteristics,
intervention and comparator characteristics, and
methods that variedwithin studies (e.g., discount rates
that were often tested in sensitivity analysis). At the
study level, there were some general characteristics
(e.g., language and funding source), methods that var-
ied only between studies (e.g., whether the study was
trial or model based), and indicators of study quality
(the QHES score31). At the country level were indica-
tors of national health care finance and resource, demo-
graphic, and epidemiological characteristics.
Model Specifications
Multilevel statistical modeling was used to inves-
tigate factors likely to explain variation in published
cost-effectiveness information.
Hierarchical model
First consider the situation in which each study
provides estimates for 1 and only 1 country. In this
case, there is a strictly hierarchical data structure,
with published estimates of DC and DE (level 1) clus-
tered in studies (level 2) andwith studies clustered in
countries (level 3). This is illustrated in the top sec-
tion of Figure 1.
A bivariate model specification was used to recog-
nize the correlation between the response variables
DC and DE, while allowing them to have different
covariates and coefficients.10,13 This also has the
advantage that the regression can be run without
assuming a particular value for the cost-effectiveness
threshold l. Let ylijk be the incremental cost and y2ijk
be the incremental effect for the i-th point estimate
reported in the j-th study for the k-th country. The
model consisted of a correlated pair of linear regres-
sion equations, with explanatory variables and error
terms on each level of the data hierarchy:
ydijk 5 b0d 1 b1dx1dijk 1 b2dx2djk 1 b3dx3dk 1 vdk
1 udjk 1 edijk d5 1; 2
For each response variable (ydijk, d = 1,2), there are 3
vectors of covariates: xldijk at the data level, x2djk at the
study level, and x3dk at the country level. The data-
level, study-level, and country-level error terms (edijk,
udjk, and vdk, respectively, d = 1,2) are assumed to fol-
low a bivariate normal distribution:
v1k
v2k
 
;BVN 0;Vvð Þ whereVv 5 s
2
v1
sv12 s
2
v2
 
u1jk
u2jk
 
;BVN 0;Vuð Þ whereVu 5 s
2
u1
su12 s
2
u2
 
e1ijk
e2ijk
 
;BVN 0;Veð Þ whereVe 5 s
2
e1
se12 s
2
e2
 
Note that the MLM framework allows both inter-
cepts and regression slopes to vary randomly, and
random slopes could be fitted to test whether the
relationships between cost-effectiveness estimates
and explanatory variables (for instance, age or base-
line cholesterol levels) differ between studies or
between countries.29,37,38 However, for simplicity,
we assumed in this exercise that only intercepts
vary randomly, whereas slopes remain fixed across
studies and countries. Thus, for example, the differ-
ence in the incremental net benefit of statins between
older patients and younger patients is assumed to be
the same in different countries
Cross-classified model
Nowconsider that some studiesmight estimate the
cost-effectiveness of an intervention for more than 1
target country, for instance, when economic evalua-
tions are conducted alongside multinational trials
or when decision models are adapted to several con-
texts. In this case, the hierarchical data structure
breaks down. The resulting cross-classified structure
is illustrated in the lower panel of Figure 1.
In MLM notation, parentheses are used to group
the subscripts for the cross-classified levels j and
k.24,29 Thus, the above model becomes
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ydiðjkÞ 5 b0d 1 b1dx1diðjkÞ 1 b2dx2dj 1 b3dx3dk
1 vdk 1 udj 1 ediðjkÞ d5 1; 2
v1k
v2k
 
;BVN 0;Vvð Þ whereVv 5 s
2
v1
sv12 s
2
v2
 
u1j
u2j
 
;BVN 0;Vuð Þ whereVu 5 s
2
u1
su12 s
2
u2
 
e1iðjkÞ
e2iðjkÞ
 
;BVN 0;Veð Þ whereVe 5 s
2
e1
se12 s
2
e2
 
Although this model is implemented with 4 levels in
MLwIN software, it is conceptually a 2-levelmodel29:
the lowest level is required to correlate the pair of lin-
ear regression equations for DC and DE, while cost-
effectiveness estimates at level 1 are clustered in
studies and countries, where both studies and coun-
tries are cross-classified at level 2. A comparable
bivariate cross-classified model has been previously
used by Goldstein and Sammons24 for school perfor-
mance research.
Statistics of Interest
The primary measure of model performance was
the deviance information criterion (DIC).39 This is
a Bayesian analogue of the Akaike information crite-
rion suitable for MLMs and combines a measure of
model fit (deviance) with an adjustment for model
complexity (the number of free parameters). A lower
DIC generally indicates a better explanation of the
data. Spiegelhalter and others39 suggested a rule of
thumb for a minimally important DIC difference of
1 to 2 points.
The aim of this study was to explore the extent of
intercountry variation in cost-effectiveness estimates
in the statin data set, after controlling for differences
attributable to studymethods, data, and assumptions.
Key statistics of interest were therefore the absolute
level of variance at the country level (s2vd, d = 1,2),
and the proportion of total variance attributed to dif-
ferences between countries: the variance partition
coefficient (VPC)29:
∆C
∆E
∆C
∆E
∆C
∆E
∆C
∆E
∆C
∆E
∆C
∆E
Study 1 Study 2
Country A
∆C
∆E
∆C
∆E
∆C
∆E
∆C
∆E
∆C
∆E
Study 3 Study 4
Country BModel 1
Three-level hierarchical model with 
cost-effecveness esmates nested 
in economic evaluaon studies and 
studies nested in countries. The 
model does not accommodate for 
data from mulnaonal studies 
(unless a separate cluster is 
introduced to pool mulnaonal 
study data at country-level)
Model 2
Cross-classified mullevel model 
with cost-effecveness data 
clustered in studies and countries. 
Studies and countries are cross-
classified, so that data from 
mulnaonal studies can be assigned 
to their respecve target countries. 
∆C: Incremental cost of intervenon; ∆E: Incremental effect of intervenon
∆C
∆E
∆C
∆E
∆C
∆E
∆C
∆E
∆C
∆E
∆C
∆E
∆C
∆E
∆C
∆E
∆C
∆E
Study 1 Study 2 Study 3
Country A Country B Country C
Figure 1 Developingmultilevelmodels to reflect complex structures in a data set of published cost-effectiveness estimates (model descrip-
tions and unit diagrams).
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VPCvd 5 s
2
vd= s
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vd1s
2
ud1s
2
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 
; d5 1; 2:
Similar absolute and relative measures of variance
were obtained for the data and study levels, but the
division of residual (subcountry) variance between
these 2 levels is somewhat arbitrary, as it relates to
authors’ choices of which parameters to vary in sub-
group and sensitivity analyses.
Estimation Procedure
The models were implemented in MLwiN soft-
ware (version 2.30, Centre for Multilevel Modelling,
Bristol, UK), using Markov chain Monte Carlo
(MCMC) estimation with initial iterative generalized
least squares to estimate priors when possible.38,40
The appropriate length of Markov chains was based
on inspection of MCMC trajectories.40
We first tested alternative model structures as var-
iance components models without covariates, as rec-
ommended in the MLM literature.29,37,38 Results are
reported for 3 specifications below. First, the cross-
classified model was used to accommodate estimates
from multinational studies alongside single-country
studies. In theoretical terms, this model provided
the most appropriate reflection of the data structure.
However, we anticipated that between-country vari-
ance estimated from single-country and multina-
tional studies might differ due to the use of
standardized study protocols anddata sourceswithin
multinational studies.25,41 To explore such effects,
wepresent 2versionsof thehierarchicalmodel: a sim-
ple hierarchical model excluding the multinational
data and a hybrid hierarchical model incorporating
the full data set but withmultinational data clustered
in a separate group on the country level. The latter
hybrid model retains information frommultinational
studies on data and study level but without con-
founding country parameters. Our prior expectation
was that the proportions of variance at the country
level (VPCvd, d = 1, 2) would be higher in the hybrid
and fully hierarchical model than in the cross-classi-
fied model. Other model specifications were tested,
including 2-level models (with only study or country
level), but these were clearly inferior to the 3
included models (as indicated by DIC statistics).
After assessing performance of variance compo-
nents models, we considered the addition of covari-
ates. We first performed extensive collinearity
checks and correspondence analyses for categorical
data. All continuous variables were centered on their
overall means, so that the intercepts represent the
predictedDCorDE for average values for each explan-
atory variable.13,29 We followed a sequential
approach by fitting the models from the bottom up
as recommended for MLMs.29,37,38 We introduced
potential covariates in subsets based on a priori rea-
soning: startingwith patient characteristics, regarded
as the most fundamental source of variability,6 then
adding differences in intervention and comparator
characteristics, and finally adding covariates that
encoded methodological variation within and then
between studies. Within each subset, the decision
over which covariates to include was based on plau-
sibility of the signs of the coefficients, the magnitude
of reduction in DIC, and statistical significance. After
specifying multivariate models with covariates on
data and study level, we used these models to further
explore whether between-country variation could be
explained by any measureable national characteris-
tics. The validity of the final models, with covariates
at all levels, was investigated graphically by plotting
the distributions of residuals at data, study, and
country level (caterpillar plots and normal probabil-
ity plots29).
RESULTS
Description of Data Set
The yield of information from the systematic
review is illustrated in the PRISMA flowchart in
Figure 2.
A total of 2094 data points with DC, DE were
extracted from 67 studies across 23 countries (Figure
3). Sixty-one studies provided cost-effectiveness esti-
mates for 1 particular country. The remaining 6 stud-
ies were multinational. These 6 studies provided 288
estimates for 16 countries, of which 6 countries were
assessed in only multinational studies. Key study
characteristics and references are listed in Supple-
mentary Appendices B and C.
Year of publication ranged from 1988 to 2009.
Industrywas involved in funding 39 studies, whereas
funding was unclear for 17 studies. Simvastatin
was the most commonly assessed intervention, and
‘‘do nothing’’ was the most common comparator,
although 17 studies compared statins. Most studies
(61) used a model, while 6 studies made use of IPD.
Subgroup analysis was usually performed with
respect to age, gender, and pretreatment cholesterol
level. QALYs were estimated in 32 studies.
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Variance Components Models
The results for the variance components models
are reported in Table 1.
All models suggested that variability in published
cost-effectiveness estimates related more to differen-
ces within and between studies than to differences in
national context: country-level VPC was no more than
Records idenfied through database 
searching
Biosis (n = 292)
Cochrane (n = 411)
CRD (n = 177)
EBSCO (n = 305)
HEED (n = 226)
OVID (n = 703)
Pubmed (n = 843)
SCOPUS (n = 833)
Web of Science* (n = 676)
Total: (n = 4466)
Sc
re
en
in
g
In
cl
ud
ed
El
ig
ib
ili
ty
Id
en
fi
ca
o
n
Addional records idenfied through other 
sources
(hand-searching references from 28 relevant review 
papers previously idenfied)
(n = 90)
Records aer duplicates removed
(n =1883)
Records excluded
(n = 1363)
Full-text arcles assessed for eligibility 
(n = 223)
(10 full-text arcles not accessible)
Full-text arcles excluded, with reasons
No original research arcle / report: (n = 96)
No cost-effecveness / cost-ulity analysis:        (n = 5)
ICER / INMB not decomposed: (n = 21)
No cost per LYS or cost per QALY: (n = 12)
Other populaon, intervenon, comparator:    (n = 15)
Language: (n = 7)
Total: (n = 156)
Full dataset
nk (countries): 21 (23†)
nj (studies): 67
ni (esmates of ΔC, ΔE):          2094
Studies included in quantave 
synthesis (MLM-analysis)
(n = 67)
Records aer brief 1st screening of 
tles and abstracts 
(n = 520)
Records aer thorough 2nd screening of 
tles and abstracts 
(n = 233)
Records excluded
(n = 287)
*    Without Medline
† England/Wales; Scotland; UK: separate geographic enes
Abbreviaons: ICER: Incremental Cost Effecveness Rao; 
INMB: Incremental Net Monetary Benefit; LYS: Life Year Saved; 
QALY: Quality Adjusted Life Year
Figure 2 Search algorithm (PRISMA flowchart).
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20%inanymodel.However, theproportionof variance
at the country level was much greater when data from
multinational studies were excluded or grouped in
a separate cluster than when they were attributed to
individual countries in the cross-classified model.
Forest plots generated from the country-level
residuals of the hierarchical hybrid model are shown
in Figure 4. This illustrates themeans and confidence
intervals for DC and DE for 17 countries as estimated
from the 61 single-country studies. The 18th category
shows the results for the group of 16 countries esti-
mated from the—comparatively homogeneous—
multinational study data, located close to the overall
regression mean.
DIC values were very similar for both models that
were run on the full data set, although the cross-
Nk (country) = 17
Nj (study) = 61
Ni (data) =1806
Countries assessed in 
‚single-country studies’ 
only
Nk (country) = 6
Nj (study) = 4
Ni (data) =88
Countries assessed in 
‚mulnaonal studies’ 
only
Nk (country) = 10
Nj (study) = 2
Ni (data) =200
Data from mulnaonal 
studies relang to 
countries also assessed in 
single-country-studies
Total:         Ni (data) =2094        Nj (study) = 67       Nk (country) = 23
Figure 3 Venn diagram illustrating the nature of the economic evaluation data.
Table 1 Variance Components Models (Without Covariates)
Model Hierarchical Model Hierarchical Hybrid Model Cross-Classified Model
How
multinational
data were
treated on
country level?
Data from multinational
studies were not included
All data from multinational
studies were included and fully
assigned to 1 extra group on
country level
All multinational study
data were included and
assigned to their respective
target countries
n (Country) 17 17 (+1) 23
n (Study) 61 67 67
n (Data) 1806 2094 2094
Response Variable DC (SE) DE (SE) DC (SE) DE (SE) DC (SE) DE (SE)
Intercept 6250 (1858) 0.403 (0.123) 6003 (1752) 0.421 (0.124) 6250 (1273) 0.449 (0.085)ffiffiffiffiffiffiffiffi
s2u0j
q
(Country) 5107 0.381 4680 0.352 1425 0.063ffiffiffiffiffiffiffiffiffi
s2u0k
q
(Study) 8564 0.564 8363 0.602 9039 0.648ffiffiffiffiffiffiffi
s2c0
q
(Data) 10936 0.501 10425 0.559 10418 0.560
Country VPC (%) 11.91 20.31 10.92 15.50 1.06 0.54
Study VPC (%) 33.48 44.54 34.88 45.38 42.49 56.91
Data VPC (%) 54.61 35.15 54.20 39.13 56.45 42.55
DIC 24,573 28,735 28,734
Note: DC = incremental cost; DE =incremental effect; DIC = deviance information criterion; SE = standard error; VPC = variance partitioning coefficient.
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classified model performed marginally better. The
DIC of the hierarchical model is not comparable to
theothermodels as thiswas runon a subset of thedata.
Multivariate Models
The next stage in our analysis was to develop mul-
tivariate models with covariates on the data and
study levels (see Table 2). The fit of the models was
improved by the inclusion of 3 sets of factors that
varied within and between studies: population char-
acteristics, the choice of intervention and compara-
tors, and certain methods of analysis. In comparison
with the variance components models (Table 1), the
DIC statistics were lower for all 3 multivariate
models.
The direction and magnitude of the estimated
coefficients were similar across the model specifica-
tions. Indicators of higher baseline CVD risk were
pooled
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associated with higher DE and lower DC: higher total
cholesterol, lower high-density lipoprotein, higher
systolic blood pressure, diabetes, and male gender.
This fits expectations, as statins have the potential
to prevent CVD events and hence to produce gains
in (quality-adjusted) life-years and reductions in
CVD-related expenditure in patients at higher risk.
Older age was associated with lower DE and DC.
This may seem counterintuitive, as older people are
at greater risk of CVD. However, older people also
have fewer years of life/QALYs to be gained from
treatment.42 CVD history was highly significant for
DE, suggesting that secondary prevention patients
tend to benefit more from statin therapy. As might
be expected, DC were positively related to interven-
tion cost and negatively related to comparator cost.
The binary variable ‘‘active comparator’’ was also sta-
tistically significant, indicating that comparisons
against another statin tended to have lower DE and
DC than comparisons against no treatment or placebo.
Regarding methodological factors, discount rates
had highly significant coefficients that were positive
for DC and negative for DE. This may be understood
by considering the likely distributions of costs and
effects over time. As a cohort ages, their CVD risk
rises, and so the total number of events avoided and
health gains from prevention by statins will also rise.
Thus, a higher discount rate results in lower DE. How-
ever, the cost of statin therapy is increasingly offset by
savings inCVD treatment over time.Ahigher discount
ratemay therefore reduceDC if the reduction in the net
present value of savings outweighs that of the costs.
Not surprisingly, DE was higher with a longer time
horizon (20 y or more). We also found that studies
modeling the effects of statins indirectly via their
effect on cholesterol levels tended to show higher DC
and DE than studies that estimated the effect on CVD
outcomes directly. Finally, we found that results
from base case analyses tended to have lower incre-
mental cost compared with results from sensitivity
analyses, potentially indicating a bias in the reporting
of sensitivity analyses in published papers.
Running models with multiple covariates on data
and study levels changed the percentage of variability
foundon country level for the fully hierarchical and the
hierarchicalhybridmodels.ThecountryVPC remained
negligible below 1% for both DC and DE in the cross-
classifiedmodel. These changes in countryVPC accord
withMLM theory, as the inclusion of lower-level cova-
riatesmay increase, reduce, or leaveunchanged thevar-
iability found on higher levels.29,37,38
We then moved on to explore whether between-
country variationwas associatedwith anymeasureable
national characteristics. However, as the number of
countries in the data set was relatively low, we tested
only 1 country covariate at a time, adding each to the
previously specified models with covariates included
on data and study level (Table 2). The estimatedmeans
and standard errors for the country-level covariates,
and the changes in DIC statistics, are shown in Table 3.
With respect to DC, we found highly significant
negative coefficients for both GDP per capita and
the percentage of GDP spent on health care in the
hierarchical and hybrid models. This accords with
Grieve and others,21 who assessed multicenter obser-
vational data of the cost and outcomes of stroke care
and found that, for centers in countries that spent
a lower percentage of GDP on health care, the inter-
vention was not cost-effective, whereas it was cost-
saving for countries with medium or high percentages
of GDP spent on health care. A potential explanation
for this is that countries that spend a higher proportion
of GDP on health caremay have higher average patient
cost, which implies higher potential cost savings from
CVD prevention.20,22 We also found highly significant
positive coefficients for government spending as a per-
centage of total health care spending. This may be due
to more rigorous cost-containment policies in coun-
tries in which health care is predominantly publicly
funded, resulting in lower average cost and less poten-
tial for future cost-savings from statin prevention. We
further found positive and significant coefficients for
population age in both the hierarchical and hybrid
model, indicating that incremental costs of statin pre-
vention are higher in older populations.
With respect to DE, we found only small but posi-
tive and significant coefficients for the percentage of
GDP spent on health care, the number of pharmacists
per 10,000 population, as well as mean population
age, body mass index, and glucose levels in either
the hierarchical or the hybrid model specifications.
The positive relationship with population-level risk
factors fully accords with prior expectations as statins
prevention should be more effective in higher-risk
groups. The same holds for the number of pharmacists
per 10,000 population, which was the only resource-
related covariate on country level for which we found
significant coefficients within the statins case study.
In general, however, variation inDEbetween countries
wasmore difficult to explain, whichmay be due to the
tendency to assume generalizability of clinical data
when populating economic models.6
BOEHLER AND LORD
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DISCUSSION
Some commentators have argued that economic
evaluation results are not transferable: ‘‘The eco-
nomic question of whether an activity adds more to
well-being than the alternative use of the same
resources in a particular community cannot be
answered by reference to the costs and consequences
of the same activity in a different community.’’43(p218)
Others have argued that transfer might sometimes be
appropriate and suggested criteria for when this
might be the case (e.g., refs. 44–46). We developed
methods to assess the extent of variation in cost-effec-
tiveness estimates that is attributable to differences
between countries and to investigate whether this
country-level variation can be explained by measure-
able factors. Thismethod could potentially be used to
provide empirical evidence to support or refute con-
tentions about the appropriateness of transferring
cost-effectiveness estimates from one context to
another.We applied ourmethod to a case study of sta-
tins for the prevention of cardiovascular disease.
Summary of Key Findings
One of the most important, and unexpected, find-
ings of our analysis was the relatively low proportion
of variation attributable to the country level as com-
pared with that at the data and study levels. The
country-level VPC differed between model specifica-
tions but never exceeded 17% for DC or 21% for DE.
This does not mean that differences between coun-
tries do notmatter in economic evaluations but rather
that theymay not be fully reflected in published cost-
effectiveness data. Barbieri and others25 explored
issues surrounding variability of economic evalua-
tions of pharmaceuticals in Western Europe and
found considerable variation between countries.
However, they did not attempt to assign variance to
differences in study questions or methods, so all
observed variability was attributed to differences
between countries.
Looking at the extent of intercountry variation esti-
mated from multinational studies, we found that by
pooling multinational data in a separate group in
the hierarchical hybrid model, estimates of country-
level variability increased as compared with the
cross-classified specification. Our finding accords
with Barbieri and others’25(p15) observation that ‘‘the
extent of variability is lower for multicountry studies
than single country studies’’ and ‘‘this may be
because, in a multicountry study, the analysts give
more active consideration to the harmonization of
data and analyses.’’ This does, however, leave us
with the question of whether the multinational
studies are underestimating true variation between
countries or whether single-country studies are over-
estimating it. Given this uncertainty, it is difficult to
conclude whether pooling of multinational and sin-
gle-study data in their respective country categories
as in the cross-classified model is appropriate.
Advantages of Our Approach
The multilevel approach allowed us to separate
effects of differenceswithin studies, between studies,
and between countries. Usingmodels that recognized
the hierarchical structure of the data, adjustment for
confounding effects and the use of a bivariate
response vector of correlated incremental costs and
effects changed the estimated proportion of variation
attributable to countries. Further improvements to
our model structure or covariates might possibly fur-
ther change these results. We cannot claim that the
final models presented are the best of all possible
models, but they did offer the best fit across a large
number of specifications tested. The estimated coeffi-
cients are generally plausible in size and direction,
and they were robust to model specification and the
inclusion of other covariates and across subsets of
data. A further strength of our analysis is that the
explanatory variables were derived systematically
from a list of factors previously suggested in the
literature.6,7
Study Limitations
An important limitation of our analysis is that it
was based on a single case study. The topic of statins
was chosen as it has been extensively researched.
However, all countries in the data set are developed
countries, with similar levels of economic and health
indicators. The generalizability of our findings to
other clinical topics and countries is uncertain.
Our model is predicated on the assumption that
the reported results of published cost-effectiveness
studies are exchangeable. This may be challenged
because of potential relationships between studies,
for instance, through common authorship, data sour-
ces, or models. As an example of the latter, we found
that estimates based on the CVD-life expectancy
model from different studies were highly depen-
dent.47 The relative similarity of estimates across
countries might therefore say more about the willing-
ness of health economists to borrow from one another
than about true commonality of cost-effectiveness in
BOEHLER AND LORD
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different contexts. The assumption of randomparam-
eters on study and country level may also be violated
as we excluded studies that did not report both DC
and DE. Earlier studies may have been more likely
to report results as incremental cost-effectiveness
ratios (ICERs; DC/DE), which may have biased the
data set toward more recent studies. This might pos-
sibly have affected the variability observed between
studies, as more recent studies may build on experi-
ences (and results) of earlier studies, which may
lead to a converging effect in terms of variability
over time.
There is also good reason to suspect cross-level
correlation between random effects on study and
country level. For instance, if national health tech-
nology assessment guidelines govern the choice of
methods, some country-level variability may be
dragged down to the study level. However, the timing
of studies ranged from 1988 to 2009, a period that
started before methods guidelines were established
and during which existing guidelines repeatedly
changed. In addition, some authors may have tar-
geted an international rather than a national audi-
ence, trying to balance different national methods
guidelines. Accordingly, we could not find a corre-
spondence between methods and countries, using
multilevel analyses or with multiple correspondence
analyses.48
Another potential objection to our approach
relates to the use of multiple cost-effectiveness esti-
mates from each published study. This adds power,
as sensitivity and subgroup analyses provide infor-
mation about variation in DE and DC as a function
of different specifications of the problem (differences
in population, intervention, and comparator) and
methodological assumptions (e.g., discount rate or
costing perspective). However, it might appear prob-
lematic that studies that report a larger number of
analyses receive more weight in our model. In the
MLM framework, study and country group means
are estimated by weighting mean raw residuals
according to the number of DC and DE estimates in
each group, as well as the variances of the within-
and between-group error terms.11,29,37,38 We tested
the impact of group sizes on group means and found
it to be small or modest for most studies included in
the analysis.49
A more usual approach in meta-regression is to
weight studies according to the precision of their
results. However, estimates of precision are not avail-
able for a large majority of cost-effectiveness studies.
This is likely to be a general characteristic of the cost-
effectiveness literature, rather than a particular flaw
in our data set. Trial-based evaluations might report
the variance for DC and DE, although they rarely
report a measure of covariance between these out-
comes. More importantly, there is a fundamental
problem in obtaining estimates of precision from
model-based economic evaluations. Uncertainty in
decisionmodels is not just a function of sampling var-
iation for the effectiveness data; it is also related to
uncertainty over a range of other input parameters
and assumptions used to extrapolate trial results or
to estimate associated costs andQALYs. These uncer-
tainties are explored using various forms of sensitiv-
ity analysis and reported in various ways, for
example, as confidence intervals around an ICER or
in a cost-effectiveness acceptability curve estimated
from a probabilistic sensitivity analysis (PSA). The
closest analogue of precision for a modeling study
would be the covariancematrix for DC and DE result-
ing from a PSA. However, this is rarely reported
directly, and furthermore, it is susceptible to bias
due to discretion over which input parameters are
included in the PSA and how uncertainty is
reflected in the form of probability distributions for
those inputs. Thus, estimates of precision from deci-
sion analytic models, when available, are rarely
compatible. We could have excluded such model-
based estimates from our analysis; however, this
would not only have severely limited the size of
our sample but, more importantly, it would also
have provided an unrepresentative sample from
the population of published cost-effectiveness
results available to inform policy decisions and
compromised our ability to investigate the transfer-
ability of that evidence base.
Areas for Further Research
A key remaining question is whether it is possible
to use our models to predict cost-effectiveness in
countries for which information is currently lacking.
The reliability of any such predictions would rest
on identification of the appropriate set of covariates
for the exchangeability assumption to hold, and
representation of the characteristics of the country
of interest by the countries in the dataset.27 How-
ever, more research is needed to establish the appro-
priate covariates and to test whether they are robust
across a wider range of countries. The contribution
of this article has been to suggest methods to start
to investigate these questions, but we believe it
would be premature to use our results to decide
whether or not to transfer or adapt results to a partic-
ular context.
VARIABILITY IN PUBLISHED COST-EFFECTIVENESS DATA
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The key priority for further research is to replicate
our approach for other clinical topics, particularly
ones for which a wider range of country estimates
might be available. We are also keen to further inves-
tigate the genealogy of economic evaluations and its
effects on variation in cost-effectiveness estimates.
Finally, further research into the development of
MLM techniques for meta-regression of cost-
effectiveness information is required.
CONCLUSION
Our analysis for the statins case study suggests that
variability in published cost-effectiveness data is pri-
marily due to differences between studies, not coun-
tries. Nevertheless, decision makers ought to be
critical before using data from other contexts because
of the additional uncertainty attached to the trans-
ferred evidence. What remains problematic is how
to find the appropriate set of covariates for the
exchangeability assumption to hold. We have set
out a possiblemethod to provide an empirical answer
to this question, but further work is needed to test the
validity of this approach and to investigate the
robustness of conclusions about the extent of varia-
tions in cost-effectiveness between countries and
whether common factors exist that are predictive of
such differences.
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